This study assessed the feasibility and utility of circulating tumor DNA (ctDNA) as a minimally invasive biomarker for monitoring treatment outcome, tracking clonal evolution, and predicting survival in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The researchers found a strong correlation between pre-treatment ctDNA concentrations and bone marrow blasts, indicating a relationship to tumor burden. Post-treatment ctDNA positivity was associated with shorter progression-free survival (PFS) and overall survival (OS). Changes in ctDNA VAF and concentration were effective prognostic biomarkers. The study also observed clonal evolution patterns in refractory/relapsed cases, demonstrating ctDNA's potential for early relapse detection.
Publisher
Clinical and Translational Medicine
Published On
Jul 20, 2023
Authors
Xinping Zhou, Wei Lang, Chen Mei, Yanling Ren, Liya Ma, Lingxu Jiang, Li Ye, Gaixiang Xu, Yingwan Luo, Lixia Liu, Shanbo Cao, Jiayue Qin, Hongyan Tong
Tags
circulating tumor DNA
myelodysplastic syndromes
acute myeloid leukemia
biomarker
prognosis
clonal evolution
treatment monitoring
Related Publications
Explore these studies to deepen your understanding of the subject.